



December 30, 2020

COVID-19: Continued Advancements in Treatment

Dear Provider:

We are closely monitoring new advancements for the treatment and prevention of COVID-19 as they are released, including the progress of vaccines and new drugs. With each new advancement, we will communicate best practices for coding and billing these new services to Blue Cross and Blue Shield of Louisiana.

Vaccines:

Blue Cross will cover the administration costs of approved COVID-19 vaccines without any member cost share for our fully insured members through December 31, 2021. Some self-funded employer groups may “opt out” of this member cost share waiver. COVID-19 vaccines that are being fully covered by the federal government should not be billed to Blue Cross.

Currently, the Pfizer and Moderna vaccines are the only to have received an Emergency Use Authorization (EUA) from the Food and Drug Administration (FDA) and are eligible for payment. Blue Cross will cover the administration costs for additional vaccines once they receive an EUA from the FDA for their administration.

Vaccines	Code Guidelines
Pfizer	<ul style="list-style-type: none"> • 91300 – vaccine • 0001A – first administration • 0002A – second administration
Moderna	<ul style="list-style-type: none"> • 91301 – vaccine • 0011A – first administration • 0012A – second administration

-over-

Antibody Treatments:

Similarly, the FDA has issued EUAs for two brands of monoclonal antibody treatments. The federal government is currently covering the full cost for these drugs. Blue Cross will cover the administration cost without any member cost share for our fully insured members through December 31, 2021, if the drug is administered in strict compliance with the FDA EUA requirements. At this time, prior authorization is not required. Some self-funded employer groups may “opt out” of this member cost share waiver. COVID-19 treatments that are being fully covered by the federal government should not be billed to Blue Cross.

Blue Cross will cover the administration costs for additional monoclonal antibody treatments as soon as they receive an EUA from the FDA for their administration.

Monoclonal Antibody	Code Guidelines
Lilly (bamlanivimab)	<ul style="list-style-type: none">• Q0239 – drug• M0239 – infusion and monitoring
Regeneron	<ul style="list-style-type: none">• Q0243 – drug• M0243 – infusion and monitoring

As more COVID-19 related treatments become available, we will update you on proper Blue Cross billing guidelines.

More Online

Be sure to visit our COVID-19 Provider Resources page, where you can access our latest provider communications. Go to www.BCBSLA.com/providers, then click on the “COVID-19 Provider Resources” link at the top of the page. We will continue to add updated information to this page as it develops.

Contact Us

If you have questions about the billing of COVID-19, you may send an email to our Provider Relations Department at provider.relations@bcbsla.com. Please put “COVID-19 Billing” in the subject line.

Thank you for all that you do for your patients—our members, especially during this COVID-19 pandemic.

Sincerely,



Hiral Arges
VP, Provider Relations and Contracting
Network Administration

HA/mdm